Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 37

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 37
---
s with and reviews the services provided by our independent registered public accounting firm. Our Audit Committee consists of four directors, John B. Bode, Wendy Dixon, Ph.D., Tamara A. Favorito and Corey Watton. Our Board has determined that each of Mr. Bode, Dr. Dixon, Ms. Favorito and Mr. Watton are independent directors under Nasdaq listing rules and under Rule 10A 3 under the Exchange Act. Ms. Favorito is the chair of the Audit Committee. Our Board has determined that each of Ms. Favorito and Mr. Bode is considered to be an “audit committee financial expert,” as defined by SEC rules and regulations, following a qualitative assessment of their level of financial expertise, knowledge and experience based on a number of factors including their previous business experience as described above, respectively, under the sections titled “Nominees for Election as a Class I Director for a Three Year Term Expiring at the 2028 Annual Meeting” and “Class II Directors Continuing in Office until the 2026 Annual Meeting.” The principal duties and responsibilities of the Audit Committee include:

| • |     | appointing and retaining an independent registered public accounting firm to audit our financial statements, assessing its independence from the Company, overseeing the independent registered public accounting firm’s work and determining the independent registered public accounting firm’s compensation; |

35

| • |     | approving in advance all audit services and non audit services to be provided to us by our independent registered public accounting firm; |

| • |     | setting hiring policies for the employees or former employees of our independent registered public accounting firm; |

| • |     | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, auditing or compliance matters, as well as for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters; |

| • |     | reviewing and discussing with management and our independent registered public accounting firm the results of the annual audit, the independent registered public accounting firm’s review of our quarterly financial statements, and our earnings press releases; |

| • |     | conferring with management and our independent registered public accounting firm about the scope, adequacy and effectiveness of our internal accounting control and our financial reporting; |

| • |     | reviewing and approving related-person transactions; |

| • |     | reviewing the results of management’s efforts to monitor compliance with our programs and policies designed to ensure adherence to applicable laws and rules, as well as to the Z